Dedicated to transforming the care of people living with Rare Genetic Disorders of Obesity

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic disorders of obesity, including:

Proopiomelanocortin
(POMC) Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
Syndrome (BBS)
Alström
Syndrome
POMC and LEPR
Heterozygous Obesity
POMC Epigenetic
Disorders*
Smith-Magenis
Syndrome Obesity
SRC1 Deficiency
Obesity
MC4R Deficiency
Obesity
SH2B1 Deficiency
Obesity

Our news

2020-03-30T08:00:00

Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations

2020-03-30T07:55:00

Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities

2020-03-18T08:00:00

Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome